Revvity, Inc.

NYSE:RVTY

Medical - Diagnostics & Research

Healthcare
$152.43 -3.36%

-$3.40 today

Market cap
$17.02B
Beta
1.11
P/E (TTM)
45.4
EPS (TTM)
$2.15
Dividend yield
0.29%
52W Low $81.22High $118.30

Volume 1.09M

Average 1.27M

RVTY Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Revvity, Inc.NYSE: RVTY

Selling, General & Admin · Q2 FY2026 · quarter ended Jul 2026

Selling, general & admin growth accelerates

Q2 FY2026 selling, general & admin of $278.58M rose 11.3% year over year, ahead of the +3.4% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 9.7% from the prior quarter. Over 3 fiscal years it compounded at +7.6% a year.

Context

  • Selling, general & admin amounted to 33.1% of revenue in FY2025, up 7.1 pp from a year earlier.
  • Selling, general & admin increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 13 analysts of $727.83M (-23.0%) for the fiscal year ending Dec 2026, a slowdown from the +32.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJul 2026
$278.58M+9.7% QoQ
Last fiscal yearDec 2025
$945.29M+32.2% YoY
LTMJul 2026
$942.58M+3.4% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.3%-27.1%-38.4 pp
1 year+32.2%-23.0%-55.2 pp
3-year CAGR+7.6%-5.0%-12.6 pp
5-year CAGR-0.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
945.29M USD
Year-over-year change
+32.2%
4-year CAGR
+6.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How RVTY compares with its peers on the latest reported figures

  • RVTY's LTM Jul 2026 selling, general & admin of $942.58M is the 6th highest of the 11 companies compared; the peer median is $938.84M.
  • Its year-over-year change of +3.4% is the 6th highest of 11, against a peer median of +3.6%.
  • Selling, general & admin amounts to 32.4% of revenue for RVTY, versus a peer median of 27.0%.
RVTY Competitors Peer median
Selling, General & Admin for RVTY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DHRDanaher CorporationLTM Sep 2026$8.12B +2.6%+4.9%31.7%
TMOThermo Fisher Scientific Inc.LTM Sep 2026$7.92B -3.4%-1.1%16.7%
AAgilent Technologies, Inc.LTM Jul 2026$1.84B +9.9%+1.4%25.0%
WATWaters CorporationLTM Jul 2026$1.21B +68.4%+4.0%26.1%
MTDMettler-Toledo International Inc.LTM Jun 2026$1.03B +7.7%+2.1%24.9%
RVTYRevvity, Inc.LTM Jul 2026$942.58M +3.4%+7.6%32.4%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$847.8M +3.3%-0.3%32.7%
CRLCharles River Laboratories International, Inc.LTM Jun 2026$753.54M -1.4%+3.8%18.8%
QGENQiagen N.V.LTM Jun 2026$586.14M +3.0%-1.1%27.9%
TECHBio-Techne CorporationLTM Sep 2026$469.88M +14.0%+8.7%38.3%
MLABMesa Laboratories, Inc.LTM Mar 2026$119.45M +3.9%+2.8%47.9%
Peer median (excluding RVTY) $938.84M+3.6%+2.5%27.0%

Competitors are the stored peer set for RVTY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.83B3.31B2.75B2.76B2.86B
Cost of Revenue1.55B1.55B1.43B1.43B1.34B
Gross Profit2.28B1.76B1.32B1.32B1.52B
Gross Margin59.6%53.2%48.1%48.0%53.1%
Research & Development200.34M221.62M216.58M196.84M215.84M
Selling, General & Admin741.61M757.99M706.12M715.3M945.29M
Operating Expenses941.95M979.61M922.7M912.14M1.16B
Depreciation & Amortization311.44M427M431.77M427.85M405.34M
EBITDA1.62B1.18B713.56M840.25M765.8M
EBITDA Margin42.2%35.7%25.9%30.5%26.8%
Operating Income1.34B781.12M399.49M410.52M356.64M
Operating Margin35.0%23.6%14.5%14.9%12.5%
Interest Income2.24M3.59M72.13M73.19M31.1M
Interest Expense102.13M103.96M98.81M96.28M92.19M
Other Income / Expenses(136.42M)(129.29M)(216.52M)(94.39M)(88.36M)
Income Before Tax1.2B651.84M182.98M316.13M268.28M
Pre-Tax Margin31.4%19.7%6.7%11.5%9.4%
Income Tax Expense314.15M139.16M3.47M33.06M25.8M
Net Income943.16M569.18M(118.38M)295.83M241.68M
Net Margin24.6%17.2%-4.3%10.7%8.5%
EPS (Basic)8.124.51(0.95)2.412.08
EPS (Diluted)8.084.50(0.95)2.412.08
Weighted Avg Shares116.17M126.16M124.7M122.76M113.21M
Weighted Avg Shares (Diluted)116.67M126.43M124.81M122.82M113.21M

Revvity, Inc.

NYSE:RVTY

Intrinsic Alpha fair value

Locked

Current Price

$152.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.